Publication Number | Title | Publication Date | Related To | Product | SIDVIM Comments |
WO2015186065A1 | Preparing 4-dimethylaminocrotonic acid or its salt used to prepare Afatinib, comprises converting 2,2-diethoxy-N,N-dimethylethanamine to ethyl-4-(dimethylamino) crotonate and hydrolyzing resultant product | 2015-12-10 | Process | Afatinib | Approval in July 2013 and priority in June 2014. Development must have started soon after the approval. |
WO2016001844A1 | New amorphous form of Afatinib dimaleate is tyrosine kinase inhibitor, useful for treating metastatic non-small cell lung cancer | 2016-01-07 | Crystalline Form | Afatinib | Not prosecuted, and could be reproducibility issue, this form would not have been commercialised and hence must have been withdrawn. |
WO2015145286A1 | New amorphous form of Baricitinib useful for treating diseases including inflammatory diseases, autoimmune disorders, diabetic nephropathy, and cancer | 2015-10-01 | Crystalline Form | Baricitinib | Approval in 2018! Development started much earlier than FDA approval. |
WO2015166434A1 | New crystalline form of Baricitinib having specified X-ray powder diffraction pattern with peaks is Janus Kinase inhibitor useful for treating inflammatory diseases, autoimmune disorders, diabetic nephropathy, and cancer | 2015-11-05 | Crystalline Form | Baricitinib | |
WO2015121769A1 | Preparing methyl N-((benzyloxy)carbonyl)-L-leucyl-L-phenylalaninate, used to prepare carfilzomib, comprises condensing methyl L-phenylalaninate or its salt with N-((benzyloxy)carbonyl)-L-leucine in the presence of boric acid | 2015-08-20 | Process | Carfilzomib | 2012 approval, Ranbaxy must have started working on the process immediately upon FDA approval and later given up the prosecution and abandoned the family! |
WO2015040571A1 | Preparing Dapagliflozin involves hydrolyzing the dapagliflozin derivative in the presence of an amine base | 2015-03-26 | Process | Dapagliflozin | Approved in January 2014, priority date of this application is 23-09-2013. Ranbaxy had started working much before FDA approval! This application is withdrawn. |
WO2015044849A1 | Preparation of ((2R,3R,4R,5S)-3,4,5-tris(acetyloxy)-6-(4-chloro-3-((4-ethoxyphenyl) methyl) phenyl) oxan-2-yl) methyl acetate used for treating type-2 diabetes mellitus, involves acetylating Dapagliflozin in solvent in absence of pyridine | 2015-04-02 | Process | Dapagliflozin | Withdrawn |
WO2015063726A1 | Preparation of 4-bromo-1-chloro-2-(4-ethoxy-benzyl)-benzene, used as intermediate to prepare Dapagliflozin, comprises reacting substituted 5-bromo-2-chloro-benzoyl compounds with phenetole and reducing the obtained reaction product | 2015-05-07 | Process | Dapagliflozin | Withdrawn |
WO2015128853A1 | Pharmaceutical composition used for treating diabetes comprises of solid dispersion of Dapagliflozin and pharmaceutical excipient | 2015-09-03 | Composition | Dapagliflozin | Unlike above Ranbaxy applications for API, this was Sun’s application for composition, it was also withdrawn in key jurisdictions. |
WO2015198227A1 | New Dapagliflozin citric acid co-crystal used in pharmaceutical composition used for treatment of type 2 diabetes mellitus | 2015-12-30 | Crystalline Form | Dapagliflozin | This was a co-crystal application by Sun. This is active in US, maybe Sun was thinking of a 505 (b) (2) filing in US. |
WO2015087239A1 | Preparation of Darapladib involves reacting 2-((4-fluorobenzyl) sulfanyl)-1,5,6,7-tetrahydro-4H-cyclopenta(d)pyrimidin-4-one with ethyl bromoacetate, hydrolyzing, and reacting with diamine in presence of boric acid (derivatives) | 2015-06-18 | Process | Darapladib | Originally a Ranbaxy application. Study failed in May 2014, priority application filed in 2013, in an anticipation of approval, which GSK never got! Ranbaxy abandoned after filing PCT. |
WO2015092687A2 | Purification of Darapladib used for treatment of atherosclerosis involves providing solution of crude Darapladib in organic solvent including n-heptane or denatured alcohol, and isolating pure Darapladib | 2015-06-25 | Process | Darapladib | Ranbaxy application, withdrawn. |
WO2015114479A1 | New crystalline forms of e.g. Darapladib oxalate, Darapladib adipate, Darapladib succinate, Darapladib phosphate or Darapladib sulfate are lipoprotein associated phospholipase-2 inhibitors useful to treat atherosclerosis | 2015-08-06 | Crystalline Form | Darapladib | |
WO2015063720A1 | Preparation of Enzalutamide used as intermediate for pharmaceuticals, involves reacting 2-((4-acetyl-3-fluorophenyl) amino)-2-methylpropanal compound with 1-isocyano-2-methyl-4-(propa-1,2-dien-1-yl)benzene, and isolating Enzalutamide | 2015-05-07 | Process | Enzalutamide | Approval of capsule in 2012. Ranbaxy must have started working on it immediately upon approval. Tablet approval in 2020 by innovator, might improve the market. |
WO2015092617A1 | Preparing Enzalutamide used to treat metastatic castration-resistant prostate cancer, comprises reacting O-phenyl carbonochloridothioate with amino-2-(trifluoromethyl)benzonitrile, and reacting product with substituted phenylamino compound | 2015-06-25 | Process | Enzalutamide | Ranbaxy application withdrawn. |
WO2015121768A1 | Preparation of Enzalutamide involves reacting 4-amino-2-fluoro-N-methylbenzamide and 1,1,1-trichloro-2-methylpropan-2-ol in alcohol, and reacting obtained compound with 4-isothiocyanato-2-(trifluoromethyl)benzonitrile | 2015-08-20 | Process | Enzalutamide | Ranbaxy application withdrawn. |
WO2015105652A1 | Treating subject after ocular surgery, involves administering composition comprising corticosteroid in vehicle that provides sustained release of corticosteroid to eye of subject | 2015-07-16 | Eye Care | Eye Care | Eye care. Application by Insite Vision Incorporated. Active only in JP. |
WO2015179527A1 | Ophthalmic formulation useful for treating or preventing ocular disease or condition comprises active agent comprising Brinzolamide, Latanoprost, Brimonidine, and/or Bosentan, polyoxyl lipid or fatty acid, and polyalkoxylated alcohol | 2015-11-26 | Composition | Eye Care | Ophthalmic product filed by Ocular Technologies. Being prosecuted in many countries. |
WO2015181802A2 | Oral pharmaceutical composition of Isotretinoin used for treating e.g. acne is prepared using process that comprises wet or dry granulation, using fluidized bed granulator or high shear mixer granulator and direct compression | 2015-12-03 | Composition | Isotretinoin | Roche decided to discontinue manufacturing due to diminishing market share, availability of many generic versions and the settling of multiple lawsuits over side effects. It continues to be manufactured as of 2019 by Absorica, Amnesteem, Claravis, Myorisan, Sotret, and Zenatane. |
WO2015186039A1 | Oral composition useful for treating e.g. acne, musculoskeletal and connective tissue inflammations and emphysema, comprises Isotretinoin, and a solvent comprising monoalkyl ether of diethylene glycol, oily vehicle and/or optionally ethanol | 2015-12-10 | Composition | Isotretinoin | Sun application, being prosecuted in many key jurisdictions. |
WO2015011609A1 | Preparation of tert-butyloxycarbonyl-protected intermediate for preparing Linagliptin for treating diabetes mellitus type-2, involves reacting quinazoline bromoxanthine intermediate with tert-butyl N-piperidinyl-carbamate intermediate | 2015-01-29 | Process | Linagliptin | |
WO2015087240A1 | Preparation of 1-(4-methyl-2-quinazolinyl)methyl-3-methyl-7-(2-butyn-1-yl)-8-bromoxanthine used for preparing Linagliptin, involves reacting 2-chloromethyl-4-methyl-quinazoline and 8-bromo-7-but-2-ynyl-3-methyl-3,7-dihydropurine-2,6-dione | 2015-06-18 | Process | Linagliptin | |
WO2014042043A9 | Pharmaceutical composition used to treat disease caused by fungus comprises Luliconazole; and at least one component of carboxylic acid, ketone, phosphoric acid, local anesthetic, antihistamine, or polyoxyethylene-based nonionic surfactant | 2015-05-21 | Composition | Luliconazole | Luliconazole, 2013 November approval. Pola must have started working on the molecule much before the approval! Priority of application September 2012! Sun Pharma acquired Pola in 2018. |
WO2014136282A8 | Luliconazole crystal for preparing pharmaceutical composition for vaginitis and pneumonia, has monoclinic crystal system having specified space group and lattice constants, and is recrystallized from alcohol optionally containing water | 2015-08-20 | Crystalline Form | Luliconazole | Luliconazole crystal |
WO2015033612A1 | New luliconazole crystals used as raw material in pharmaceutical composition for providing antifungal effect and treating fungal diseases e.g. dermatomycosis | 2015-03-12 | Crystalline Form | Luliconazole | Lot of work is being done on Luliconazole in 2013-2014. |
WO2015076352A1 | Pharmaceutical composition used for treating pneumonia associated with Fusarium fungus and potentially with protozoan and/or intracellular parasite as causative microorganism, comprises Luliconazole or Lanoconazole | 2015-05-28 | Composition | Luliconazole | |
WO2015166472A1 | Extended-release liquid composition of Metformin used for treating type II diabetes comprises cores of Metformin coated with release controlling polymer, and suspension base | 2015-11-05 | Composition | Metformin | |
WO2015004617A1 | Timed extended-release pharmaceutical composition useful for treating e.g. hypertension, comprises core comprising Metoprolol; extended-release coating comprising extended-release polymer; and outer coating layer comprising enteric polymer | 2015-01-15 | Composition | Metoprolol | Metoprolol ER is always difficult to make formulation. Ranbaxy must have tried to develop a bioequivalent formulation. Perhaps it would not have met BE and hence later withdrew or stopped prosecution. |
WO2015040573A1 | New mirabegron dimethylsulfoxide solvate having specified X-ray diffraction peaks is beta-3 adrenergic agonist used to treat overactive bladder with symptoms of urinary incontinence, urgency and urinary frequency | 2015-03-26 | Crystalline Form | Mirabegron | Mirabegron June 2012 approval and September 2013 Polymorph application! |
WO2015040605A1 | New crystalline form of mirabegron useful for treating urinary incontinence, urgency and urinary frequency | 2015-03-26 | Crystalline Form | Mirabegron | |
WO2015130957A1 | New substituted heterocyclic compounds are sodium channel, voltage gated, type IX alpha subunit inhibitors useful for treating e.g. pain, epilepsy, Parkinson's disease, mood disorders, psychosis, tinnitus and amyotrophic lateral sclerosis | 2015-09-03 | NCE | NCE | New compounds by filed by Zalicus Pharmaceuticals, Ltd. Sun acquired Canadian company in 2015. This application is still under prosecution in US. Something could be interesting here. |
WO2015173590A1 | New isolated polypeptide useful for transformation of (S)-reticuline to (R)-reticuline and for producing Papaver plant, comprises domain comprising specific amino acid sequence | 2015-11-19 | NCE | NCE | Application filed by The University of York, Sun Pharmaceutical Industries (Australia) Pty Limited. Application granted in US, being prosecuted in EU, AU and few other countries. Something must be very interesting here in cDNA nucleotide sequence. |
WO2015092624A1 | New Nilotinib mono-oxalate is kinase inhibitor useful for e.g. treating adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia in chronic phase | 2015-06-25 | Crystalline Form | Nilotinib | 2007 approval. Launch possible in 2023. However, this Ranbaxy application is withdrawn. |
WO2015001488A1 | Extended-release tablet of Paliperidone used to treat neurological disorders, comprises core comprising first and second drug layer comprising e.g. rate-controlling polymer, seal coating layer, and extended-release coating | 2015-01-08 | Composition | Paliperidone | First ER composition approved in 2006. This must be reasonably late filing by Ranbaxy and hence later withdrawn. |
WO2015015390A1 | Closure assembly for dispensing liquid drug formulation to patient, has metered dosing system installed upon liquid drug formulation container and comprising cap with piston attached to cap, doser, and dip tube attached to doser | 2015-02-05 | Platform | General Purpose | Ranbaxy application for dispensing metered dose. This could not have prosecuted due to commercial unattractiveness of the product. |
WO2015028972A1 | Pulsatile-release dosage form, useful for treating e.g. hypertension, Parkinson's syndrome and arthritis, comprises core comprising drug and excipients, and coating layer comprising water-soluble polymer and water-insoluble polymer | 2015-03-05 | Platform | General Purpose | Ranbaxy application, withdrawn. |
WO2015044880A1 | Palatable oral liquid composition useful for treating diabetes, comprises a dipeptidyl peptidase-IV inhibitor, and an excipient | 2015-04-02 | Platform | General Purpose | Ranbaxy application, withdrawn. |
WO2015071859A1 | Oral dispersible composition useful for treating diabetes, comprises dipeptidyl peptidase 4 inhibitor and excipients | 2015-05-21 | Platform | General Purpose | Diabetes treatment, Ranbaxy application, withdrawn. |
WO2015087241A1 | Crush-resistant oral solid dosage form comprises a drug prone to abuse, and chewing gum base comprising chewable plastic polymer e.g. polyisobutylene, butadiene styrene and terpene resins | 2015-06-18 | Platform | General Purpose | Chewing gum-based composition. Ranbaxy application, withdrawn. |
WO2015145459A1 | Immediate release biphasic matrix solid dosage form useful as abuse deterrent, comprises intragranular phase comprising drug susceptible to abuse and reverse enteric polymer, and extragranular phase comprising alkalizer | 2015-10-01 | Platform | General Purpose | Sun Pharma application, being prosecuted in many jurisdictions. Must be an interesting composition. |
WO2015166473A1 | Extended-release suspension composition comprises multiple coated cores comprising core which comprises active ingredient, and coating layer over core comprising release-controlling polymers, and suspension base | 2015-11-05 | Platform | General Purpose | Sun Pharma application, being prosecuted in many jurisdictions. Must be an interesting composition. |
WO2015186040A1 | Clear nanoemulsion composition used to treat e.g. heart disorder and attention deficit disorder, comprises active ingredient, oily phase comprising medium-chain or short-chain glycerides, surfactant, optionally co-solvent, and aqueous phase | 2015-12-10 | Platform | General Purpose | Nanoemulsion composition by Sun Pharma. Abandoned! |
WO2015114509A1 | Stabilized gastroretentive tablet comprises Pregabalin, swellable polymer, pH modifier, and other excipients | 2015-08-06 | Composition | Pregabalin | Ranbaxy application, abandoned. |
WO2015011617A1 | Preparing 5-chloro-N-(2-hydroxy-3-((4-(3-oxo-4-morpholinyl)-phenyl) amino) propyl)-thiophenecarboxamide intermediate for Rivaroxaban, comprises reacting 5-chloro-N-(2-oxiranylmethyl)-2-thiophenecarboxamide with 4-(4-aminophenyl) morpholinone | 2015-01-29 | Process | Rivaroxaban | Rivaroxaban approved in November 2013, originally Ranbaxy application filed in July 2013. Ranbaxy must have started working on molecule soon after approval. Later did not prosecute, could be commercially non-viable process. |
WO2015166466A1 | New crystalline Saxagliptin acetate form II is dipeptidyl peptidase IV enzyme inhibitor, useful for treating type 2 diabetes mellitus | 2015-11-05 | Crystalline Form | Saxagliptin | 2009 approval, Sun Pharma application, withdrawn |
WO2015071887A1 | Oral pharmaceutical composition useful in treatment of type-II diabetes mellitus, comprises core comprising Saxagliptin, and coating layer comprising coating polymer, surrounding core | 2015-05-21 | Composition | Saxagliptin | Ranbaxy application, withdrawn. |
WO2015071889A1 | Oral composition used to treat type 2 diabetes mellitus, comprises core, optionally seal layer comprising coating polymer coated over the core, drug layer comprising Saxagliptin and coating polymer and outer layer comprising coating polymer | 2015-05-21 | Composition | Saxagliptin | Ranbaxy application, withdrawn. |
WO2015087262A1 | Preparing Saxagliptin which is useful for treating type 2 diabetes mellitus comprises e.g. deprotecting ((S)-2-((1S,3S,5S)-3-cyano-2-aza-bicyclo (3.1.0) hex-2-yl)-1-(3-hydroxy-adamantan-1-yl)-2-oxo-ethyl)-carbamic acid tert-butyl ester | 2015-06-18 | Process | Saxagliptin | Ranbaxy application, withdrawn. |
WO2015145333A1 | Preparing Sitagliptin, comprises treating (3R)-3-((tert-butoxycarbonyl) amino)-4-(2,4,5-trifluorophenyl) butanoic acid with 3-(trifluoromethyl)-5,6,7,8-tetrahydro (1,2,4) triazolo(4,3-a) pyrazine, and deprotecting the obtained product | 2015-10-01 | Process | Sitagliptin | Sun Pharma application, withdrawn. |
WO2014039340A3 | Method of inhibiting growth of hair in skin, involves epilation of follicles in the skin, waiting until within five days of commencement of metanagen, applying photodynamic agent to skin, and exposing skin to photoactivating light | 2015-07-16 | Skin Care | Skin Care | Application filed by Dusa Pharmaceuticals, Inc. Sun Pharma acquired Dusa. This is being prosecuted in key countries. |
WO2015005419A1 | Composition useful for preparing topical foam formulation, comprises N-alkyl-2-pyrrolidone, carbonate diester, and surfactant | 2015-01-15 | Composition | Skin Care | |
WO2015015384A1 | Topical applicator for use by patient for applying e.g. ointment, onto affected area and massaging area during treatment of muscle aches, has tube for containing semi-solid dosage form, and massaging assembly snap-sealed to neck region | 2015-02-05 | Skin Care | Skin Care | Originally Ranbaxy application, which was not prosecuted, maybe due to commercial reasons. |
WO2015044857A1 | Topical spray composition used for treating a topical skin condition (e.g. dermatoses, psoriasis and eczema) comprises Halobetasol, emollient, non-aqueous solvent, and propellant | 2015-04-02 | Skin Care | Skin Care | Ranbaxy application prosecuted in Mexico! Business of this composition in Mexico? |
WO2015063723A1 | Stable topical pharmaceutical composition useful for treating skin disorder e.g. psoriasis, keratosis, eczema, rosacea, acne vulgaris, dermatitis and pruritus, comprises acitretin, and one or more gelling agents | 2015-05-07 | Skin Care | Skin Care | Ranbaxy application, prosecuted in many countries and must be interesting. |
WO2015092602A1 | Topical pharmaceutical composition of retinoid useful for treating acne, comprises microspheres comprising retinoid and microsphere-forming polymers, and coating layer | 2015-06-25 | Skin Care | Skin Care | Ranbaxy application, withdrawn. |
WO2015107542A2 | Treating acne or psoriasis, by topically administering Tazarotene free of dimer impurity | 2015-07-23 | Skin Care | Skin Care | Sun Pharma application, being prosecuted in few countries including US. |
WO2015147296A1 | Producing composition used as skin external preparation for treating inflammation, by cooling oil-in-water emulsion to or below cloud point of non-ionic surfactant, adding carboxyvinyl polymer and neutralizing with alkali agent | 2015-10-01 | Skin Care | Skin Care | Withdrawn in many countries. |
WO2015156219A1 | External pharmaceutical composition used for treating dermatomycosis, comprises acetonitrile derivative and steroids including Dexamethasones, Hydrocortisones, Clobetasones, Clobetasols, Betamethasones, and Mometasones | 2015-10-15 | Skin Care | Skin Care | Withdrawn in many countries |
WO2015056247A1 | Pure crystalline form-II of L-malic acid salt of Sunitinib used as oral multi-kinase inhibitor and is useful for treatment of gastrointestinal stromal tumors and advanced renal cell carcinoma | 2015-04-23 | Crystalline Form | Sunitinib | Ranbaxy application, granted in US |
WO2015056250A1 | New ascorbic acid salt of Sunitinib useful for treating or preventing a protein kinase related disorder, and gastrointestinal stromal tumors and advanced renal cell carcinoma | 2015-04-23 | Composition | Sunitinib | Ranbaxy application, granted in US |
WO2015075744A1 | Preparing Tapentadol useful as analgesic, comprises reacting (2S,3R)-1-(dimethylamino)-3-(3-methoxyphenyl)-2-methylpentan-3-ol with isocyanate followed by hydrogenating and dimethylation | 2015-05-28 | Process | Tapentadol | Sun application, being prosecuted in many key jurisdictions. |
WO2015019238A1 | Manufacture of N-protected (5S) (thiazolidinylcarbonyl) pyrrolidin-3-one for manufacturing (3-methylphenyl-1H-pyrazolyl) piperazinyl-pyrrolidinyl (thiazolidinyl) methanone, involves condensing N-protected oxo-1-proline with thiazolidine | 2015-02-12 | Process | Teneligliptin | Teneligliptin approved for use in Japan, Argentina, Korea and India, in 2012-2013. Ranbaxy must have started working upon approval. No approval in other countries! Family withdrawn. |
WO2015019239A1 | Preparing 1-(3-methyl-1-phenyl-1H-pyrazol-5-yl) piperazine comprises e.g. reacting substituted protected piperazine compounds with alkylacetoacetate and phenylhydrazine, and cyclizing the resultant | 2015-02-12 | Process | Teneligliptin | Ranbaxy application, withdrawn. |
WO2015063709A1 | Preparation of 1-(3-methyl-1-phenyl-1H-pyrazol-5-yl) piperazine or its salt used for preparation of (1,3-thiazolidin-3-yl) methanone derivative or its salt involves cyclizing aniline derivative in presence of Lawesson's reagent | 2015-05-07 | Process | Teneligliptin | Ranbaxy application, withdrawn |
WO2015001489A1 | Composition, useful for treating cardiovascular diseases such as thrombotic cardiovascular events e.g. unstable angina, comprises amorphous ticagrelor, and excipients including diluent, binder, disintegrant and/or lubricant | 2015-01-08 | Composition | Ticagrelor | Ticagrelor is 2011 approval. Priority of this application is 2013 and it is clear Ranbaxy must be working on Ticagrelor immediately after the approval. Sun now doesn't seem to be interested in this composition, application withdrawn. |
WO2015198225A1 | Dry process to make composition comprising Tofacitinib, and diluent, disintegrant or excipient by dry granulation, comprises blending Tofacitinib and diluent, blending with disintegrant and diluent, blending with lubricant and compressing | 2015-12-30 | Composition | Tofacitinib | First approval in 2018! Sun filed composition patent application of Tofacitinib in 2014! Work on the molecule must have started at least two-three years prior to 2014. They must have prepared API for FDF development! Sun withdrew application in most of the jurisdiction, perhaps thought against of approval and had not prosecuted! |
WO2015056219A1 | Preparing micronized Valsartan, useful for treatment of hypertension and heart failure, comprises subjecting Valsartan to drying and micronization simultaneously | 2015-04-23 | Composition | Valsartan | Ranbaxy application, withdrawn. |
WO2015019237A1 | Composition used to treat or prevent CNS disorder e.g. major depressive disorder, anxiety disorders, bipolar disorders, mania, eating disorders or sleeping disorders, comprises micronized particles of Vilazodone, and excipient e.g. binder | 2015-02-12 | Composition | Vilazodone | Vilazodone approved in 2011, application filed in 2013, this is another example where Ranbaxy would have started FDF development immediately after approval! Now withdrawn, composition or product must be uninteresting to Sun now. |
WO2015019256A1 | Pharmaceutical composition used for treating and/or preventing central nervous system disorder, e.g. major depressive disorder, comprises Vilazodone and nonionic surfactants | 2015-02-12 | Composition | Vilazodone | Ranbaxy application, withdrawn. |
WO2016001843A1 | Extended-release gastroretentive tablet of Voglibose for once-a-day therapy useful for treating diabetes, comprises Voglibose and release controlling polymers | 2016-01-07 | Composition | Voglibose | Takeda’s old product did not do well outside Japan. Sun Pharma application, now withdrawn. |
